The estimated Net Worth of Gary Wilcox is at least $27.5 Milhão dollars as of 1 September 2016. Gary Wilcox owns over 10,000 units of Cocrystal Pharma Inc stock worth over $27,287,254 and over the last 10 years he sold COCP stock worth over $0. In addition, he makes $201,000 as Chairman of the Board e Chief Executive Officer at Cocrystal Pharma Inc.
Gary has made over 3 trades of the Cocrystal Pharma Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of COCP stock worth $4,100 on 1 September 2016.
The largest trade he's ever made was buying 54,348 units of Cocrystal Pharma Inc stock on 25 March 2015 worth over $50,000. On average, Gary trades about 18,895 units every 88 days since 2015. As of 1 September 2016 he still owns at least 16,948,605 units of Cocrystal Pharma Inc stock.
You can see the complete history of Gary Wilcox stock trades at the bottom of the page.
Dr. Gary L. Wilcox Ph.D. serves as Chairman of the Board, Chief Executive Officer of the Company. From January 2, 2014 until March 11, 2015, Dr. Wilcox served as the Chairman of the Board (Co-Chairman beginning November 25, 2014) and Chief Executive Officer of Cocrystal. He is a co-founder of Cocrystal Discovery and served as its Chief Executive Officer from 2008 through March 2015. Since 2012, Dr. Wilcox has been a director of the Daily Journal Corporation (Nasdaq:DJCO), a publisher of legal newspapers and websites, and a developer of legal case management software. From 1993 to 2007, Dr. Wilcox served as Executive Vice President of Operations and a member of the Board of Directors of Icos Corporation (Nasdaq:ICOS), where he played a key role in the development of Cialis, a drug with annual sales of $2 billion. In 1982, Dr. Wilcox co-founded Ingene Inc. (Nasdaq:IGEI), serving as its Chairman, President and CEO through private financings, an IPO and a successful merger with XOMA Corporation (Nasdaq:XOMA) in 1989. From 1989-1993 Dr. Wilcox was Vice Chairman of the Board of Directors and Executive Vice President of Xoma. From 1974 until 1984, Dr. Wilcox was a Professor of Microbiology and a member of the Molecular Biology Institute at UCLA. He has served on 15 boards of directors including Nasdaq, New York and London stock exchange companies as well as private technology companies.
As the Chairman of the Board e Chief Executive Officer of Cocrystal Pharma Inc, the total compensation of Gary Wilcox at Cocrystal Pharma Inc is $201,000. There are 5 executives at Cocrystal Pharma Inc getting paid more, with James J. Martin CPA, CPA, M.B.A., MBA having the highest compensation of $331,000.
Gary Wilcox is 73, he's been the Chairman of the Board e Chief Executive Officer of Cocrystal Pharma Inc since 2020. There are 2 older and 7 younger executives at Cocrystal Pharma Inc. The oldest executive at Cocrystal Pharma Inc is Phillip Frost, 83, who is the Independent Director.
Gary's mailing address filed with the SEC is 2007 148TH ST. S.E., , SNOHOMISH, WA, 98012.
Over the last 10 years, insiders at Cocrystal Pharma Inc have traded over $2,664,250 worth of Cocrystal Pharma Inc stock and bought 23,366,560 units worth $16,815,201 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Phillip Md Et Al Frost, eJane Ph D Hsiao. On average, Cocrystal Pharma Inc executives and independent directors trade stock every 113 days with the average trade being worth of $1,616,422. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 4 April 2023, trading 1,015,229 units of COCP stock currently worth $2,000,001.
cocrystal (otcqb:cocp) is a pharmaceutical company seeking to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. cocrystal employs unique technologies and nobel prize winning expertise to create first- and best-in-class antiviral drugs. these technologies, including our nucleoside chemistry expertise and market-focused approach to drug discovery are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. the company has identified promising, preclinical stage antiviral compounds for the unmet medical needs including hepatitis, influenza and norovirus infections. cocrystal has previously received strategic investments from teva pharmaceuticals, opko health (opk), dr. raymond schinazi, brace pharmaceutical, llc, and the frost group.
Cocrystal Pharma Inc executives and other stock owners filed with the SEC include: